<DOC>
	<DOC>NCT00478322</DOC>
	<brief_summary>Purpose: A 28-day US study in patients with type 2 diabetes mellitus to assess the safety and tolerability as well as the effects of treatment with an investigational drug.</brief_summary>
	<brief_title>Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>1. Have an established diagnosis of Type 2 Diabetes as determined by the investigator. 2. Females will be postmenopausal for at least 1 year with documented FSH &gt; 30 IU/L. 1. Hypertriglyceridemia &gt; 500 mg/dL at screening. 2. BMI &gt; 40 kg/m2. 3. Receiving thiazolidinediones, insulin, or exenatide within the 3 months prior to screening. 4. History or clinical manifestations of Addison's disease, Cushing's Syndrome, or other disorders involving glucocorticoids or mineralocorticoids. 5. Current treatment or treatment within 30 days or five halflives (whichever is longer) prior to the first dose of study medication with another investigational medication or current enrollment in another investigational protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Diabetes;</keyword>
	<keyword>Type II diabetes;</keyword>
	<keyword>Non-insulin dependent diabetes;</keyword>
	<keyword>Obesity</keyword>
</DOC>